Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,910 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PARP Inhibitors as P-glyoprotein Substrates.
Lawlor D, Martin P, Busschots S, Thery J, O'Leary JJ, Hennessy BT, Stordal B. Lawlor D, et al. Among authors: martin p. J Pharm Sci. 2014 Jun;103(6):1913-20. doi: 10.1002/jps.23952. Epub 2014 Apr 3. J Pharm Sci. 2014. PMID: 24700236
Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation.
Zinter MS, Dvorak CC, Mayday MY, Reyes G, Simon MR, Pearce EM, Kim H, Shaw PJ, Rowan CM, Auletta JJ, Martin PL, Godder K, Duncan CN, Lalefar NR, Kreml EM, Hume JR, Abdel-Azim H, Hurley C, Cuvelier GDE, Keating AK, Qayed M, Killinger JS, Fitzgerald JC, Hanna R, Mahadeo KM, Quigg TC, Satwani P, Castillo P, Gertz SJ, Moore TB, Hanisch B, Abdel-Mageed A, Phelan R, Davis DB, Hudspeth MP, Yanik GA, Pulsipher MA, Sulaiman I, Segal LN, Versluys BA, Lindemans CA, Boelens JJ, DeRisi JL; Pediatric Transplantation and Cell Therapy Consortium. Zinter MS, et al. Among authors: martin pl. Nat Med. 2024 May 23. doi: 10.1038/s41591-024-02999-4. Online ahead of print. Nat Med. 2024. PMID: 38783139
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Goodyear CS, Patel A, Barnes E, Willicombe M, Siebert S, de Silva TI, Snowden JA, Lim SH, Bowden SJ, Billingham L, Richter A, Carroll M, Carr EJ, Beale R, Rea D, Parry H, Pirrie S, Lim Z, Satsangi J, Dunachie SJ, Cook G, Miller P, Basu N, Gilmour A, Hodgkins AM, Evans L, Hughes A, Longet S, Meacham G, Yong KL, A'Hearne MJ, Koh MBC, Burns SO, Orchard K, Paterson C, McIlroy G, Murray SM, Thomson T, Dimitriadis S, Goulston L, Miller S, Keillor V, Prendecki M, Thomas D, Kirkham A, McInnes IB, Kearns P; OCTAVE-DUO investigators. Goodyear CS, et al. Lancet Rheumatol. 2024 Jun;6(6):e339-e351. doi: 10.1016/S2665-9913(24)00065-1. Epub 2024 May 8. Lancet Rheumatol. 2024. PMID: 38734019 Free article. Clinical Trial.
Lack of p38 activation in T cells increases IL-35 and protects against obesity by promoting thermogenesis.
Nikolic I, Ruiz-Garrido I, Crespo M, Romero-Becerra R, Leiva-Vega L, Mora A, León M, Rodríguez E, Leiva M, Plata-Gómez AB, Alvarez Flores MB, Torres JL, Hernández-Cosido L, López JA, Vázquez J, Efeyan A, Martin P, Marcos M, Sabio G. Nikolic I, et al. Among authors: martin p. EMBO Rep. 2024 May 10. doi: 10.1038/s44319-024-00149-y. Online ahead of print. EMBO Rep. 2024. PMID: 38730210 Free article.
7,910 results